International Immunology, Vol. 12, No. 4, 537-546,
April 2000
© 2000 Japanese Society for Immunology
Evidence for in situ expansion of diverse antitumor-specific cytotoxic T lymphocyte clones in a human large cell carcinoma of the lung
Laboratoire Cytokines et Immunologie des tumeurs Humaines, U487 INSERM, Institut Gustave Roussy, 94805 Villejuif Cedex, France
1 Département Thoracique, Institut Montsouris, 75013 Paris, France
Correspondence to: F. Mami-Chouaib
We have isolated several cytotoxic T lymphocyte (CTL) clones from lymphocytes infiltrating a human large cell carcinoma (LCC) of the lung. All these clones were found to express a CD3+, TCR
ß+, CD8+, CD4, CD28 phenotype. According to their TCR ß chain variable region expression, they were divided in three major groups. The first group, including the majority of the clones, expressed a unique Vß3Jß1.2 TCR. The second group expressed a Vß22Jß1.4 rearrangement and the third group, including only two clones, expressed a Vß8Jß1.5 TCR. Functional studies showed that all the CTL clones mediated a high cytotoxic activity against the autologous tumor cell line. While the Vß3+ clones showed a weak lysis against few allogeneic non-small cell lung cancer (NSCLC) tumor cell lines, Vß8+ and Vß22+ T cell clones were able to kill a panel of allogeneic NSCLC tumor cell lines. Cytotoxicity-blocking experiments using specific mAb indicated that, while the Vß3+ and Vß22+ CTL clones were HLA-A2 restricted, the Vß8+ clones appeared HLA-B or -C restricted. TCR transcripts expressed in the cloned cells were determined by CDR3 size and sequence analyses, and compared to those present in fresh tumor tissue. Interestingly, our studies demonstrated that the CTL clones identified in vitro were selectively expanded in vivo at the tumor site as compared to autologous peripheral blood lymphocytes. These results further provide evidence that an immune response may take place in NSCLC and that effector T cells may contribute to tumor regression.
Keywords: cytotoxic T lymphocyte, non-small cell lung cancer, TCR, tumor-associated antigen, tumor-infiltrating lymphocyte
Transmitting editor: J. F. Bach
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
K. Franciszkiewicz, A. Le Floc'h, A. Jalil, F. Vigant, T. Robert, I. Vergnon, A. Mackiewicz, K. Benihoud, P. Validire, S. Chouaib, et al. Intratumoral Induction of CD103 Triggers Tumor-Specific CTL Function and CCR5-Dependent T-Cell Retention Cancer Res., August 1, 2009; 69(15): 6249 - 6255. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. K. Bauer and E. A. Rondini REVIEW PAPER: The Role of Inflammation in Mouse Pulmonary Neoplasia Vet. Pathol., May 1, 2009; 46(3): 369 - 390. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Z. Noman, S. Buart, J. Van Pelt, C. Richon, M. Hasmim, N. Leleu, W. M. Suchorska, A. Jalil, Y. Lecluse, F. El Hage, et al. The Cooperative Induction of Hypoxia-Inducible Factor-1{alpha} and STAT3 during Hypoxia Induced an Impairment of Tumor Susceptibility to CTL-Mediated Cell Lysis J. Immunol., March 15, 2009; 182(6): 3510 - 3521. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. El Hage, V. Stroobant, I. Vergnon, J.-F. Baurain, H. Echchakir, V. Lazar, S. Chouaib, P. G. Coulie, and F. Mami-Chouaib Preprocalcitonin signal peptide generates a cytotoxic T lymphocyte-defined tumor epitope processed by a proteasome-independent pathway PNAS, July 22, 2008; 105(29): 10119 - 10124. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. L. Floc'h, A. Jalil, I. Vergnon, B. L. M. Chansac, V. Lazar, G. Bismuth, S. Chouaib, and F. Mami-Chouaib {alpha}E{beta}7 integrin interaction with E-cadherin promotes antitumor CTL activity by triggering lytic granule polarization and exocytosis J. Exp. Med., March 19, 2007; 204(3): 559 - 570. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Abouzahr, G. Bismuth, C. Gaudin, O. Caroll, P. Van Endert, A. Jalil, J. Dausset, I. Vergnon, C. Richon, A. Kauffmann, et al. Identification of target actin content and polymerization status as a mechanism of tumor resistance after cytolytic T lymphocyte pressure PNAS, January 31, 2006; 103(5): 1428 - 1433. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Le Maux Chansac, A. Moretta, I. Vergnon, P. Opolon, Y. Lecluse, D. Grunenwald, M. Kubin, J.-C. Soria, S. Chouaib, and F. Mami-Chouaib NK Cells Infiltrating a MHC Class I-Deficient Lung Adenocarcinoma Display Impaired Cytotoxic Activity toward Autologous Tumor Cells Associated with Altered NK Cell-Triggering Receptors J. Immunol., November 1, 2005; 175(9): 5790 - 5798. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Dorothee, I. Vergnon, F. El Hage, B. L. M. Chansac, V. Ferrand, Y. Lecluse, P. Opolon, S. Chouaib, G. Bismuth, and F. Mami-Chouaib In Situ Sensory Adaptation of Tumor-Infiltrating T Lymphocytes to Peptide-MHC Levels Elicits Strong Antitumor Reactivity J. Immunol., June 1, 2005; 174(11): 6888 - 6897. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Thiery, S. Abouzahr, G. Dorothee, A. Jalil, C. Richon, I. Vergnon, F. Mami-Chouaib, and S. Chouaib p53 Potentiation of Tumor Cell Susceptibility to CTL Involves Fas and Mitochondrial Pathways J. Immunol., January 15, 2005; 174(2): 871 - 878. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Ladanyi, B. Somlai, K. Gilde, Z. Fejos, I. Gaudi, and J. Timar T-Cell Activation Marker Expression on Tumor-Infiltrating Lymphocytes As Prognostic Factor in Cutaneous Malignant Melanoma Clin. Cancer Res., January 15, 2004; 10(2): 521 - 530. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Dangles-Marie, S. Richon, M. El Behi, H. Echchakir, G. Dorothee, J. Thiery, P. Validire, I. Vergnon, J. Menez, M. Ladjimi, et al. A Three-Dimensional Tumor Cell Defect in Activating Autologous CTLs Is Associated with Inefficient Antigen Presentation Correlated with Heat Shock Protein-70 Down-Regulation Cancer Res., July 1, 2003; 63(13): 3682 - 3687. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Thiery, G. Dorothee, H. Haddada, H. Echchakir, C. Richon, R. Stancou, I. Vergnon, J. Benard, F. Mami-Chouaib, and S. Chouaib Potentiation of a Tumor Cell Susceptibility to Autologous CTL Killing by Restoration of Wild-Type p53 Function J. Immunol., June 15, 2003; 170(12): 5919 - 5926. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Dorothee, I. Vergnon, J. Menez, H. Echchakir, D. Grunenwald, M. Kubin, S. Chouaib, and F. Mami-Chouaib Tumor-Infiltrating CD4+ T Lymphocytes Express APO2 Ligand (APO2L)/TRAIL upon Specific Stimulation with Autologous Lung Carcinoma Cells: Role of IFN-{alpha} on APO2L/TRAIL Expression and -Mediated Cytotoxicity J. Immunol., July 15, 2002; 169(2): 809 - 817. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Echchakir, G. Dorothee, I. Vergnon, J. Menez, S. Chouaib, and F. Mami-Chouaib Cytotoxic T lymphocytes directed against a tumor-specific mutated antigen display similar HLA tetramer binding but distinct functional avidity and tissue distribution PNAS, July 9, 2002; 99(14): 9358 - 9363. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Echchakir, F. Mami-Chouaib, I. Vergnon, J.-F. Baurain, V. Karanikas, S. Chouaib, and P. G. Coulie A Point Mutation in the {{alpha}}-Actinin-4 Gene Generates an Antigenic Peptide Recognized by Autologous Cytolytic T Lymphocytes on a Human Lung Carcinoma Cancer Res., May 1, 2001; 61(10): 4078 - 4083. [Abstract] [Full Text] |
||||





